×
Merck Receivables 2010-2024 | MKKGY
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Merck receivables for the quarter ending December 31, 2024 were
$4.825B
, a
0.42% decline
year-over-year.
Merck receivables for 2024 were
$4.825B
, a
0.42% decline
from 2023.
Merck receivables for 2023 were
$4.845B
, a
0.85% increase
from 2022.
Merck receivables for 2022 were
$4.804B
, a
1.86% decline
from 2021.
View More
Merck Receivables 2010-2024 | MKKGY
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Merck receivables for 2024 were
$4.825B
, a
0.42% decline
from 2023.
Merck receivables for 2023 were
$4.845B
, a
0.85% increase
from 2022.
Merck receivables for 2022 were
$4.804B
, a
1.86% decline
from 2021.
Related Stocks
Company Name
Market
Cap
Chugai Pharmaceutical (CHGCY)
$95B
Zoetis (ZTS)
$66.3B
Takeda Pharmaceutical (TAK)
$46.8B
Daiichi Sankyo, - (DSNKY)
$41.7B
Summit Therapeutics (SMMT)
$18.2B
Sandoz Group AG (SDZNY)
$17.7B
Astellas Pharma (ALPMY)
$16.9B
Shionogi (SGIOY)
$14.1B
United Therapeutics (UTHR)
$12.8B
Neurocrine Biosciences (NBIX)
$10B
IPSEN (IPSEY)
$8.6B
Orion OYJ (ORINY)
$8B
Madrigal Pharmaceuticals (MDGL)
$6.7B
Stevanato Group S.p.A (STVN)
$6.6B
Corcept Therapeutics (CORT)
$6.6B
Hikma Pharmaceuticals Plc (HKMPF)
$5.8B
Ono Pharmaceutical (OPHLF)
$5.5B
Grifols, S.A (GRFS)
$4.9B
Ionis Pharmaceuticals (IONS)
$4.5B
Soleno Therapeutics (SLNO)
$3.2B
Crinetics Pharmaceuticals (CRNX)
$2.8B
Catalyst Pharmaceuticals (CPRX)
$2.7B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.3B
Recursion Pharmaceuticals (RXRX)
$2.2B
Hypermarcas (HYPMY)
$2.1B
NewAmsterdam Pharma (NAMS)
$1.8B
Centessa Pharmaceuticals (CNTA)
$1.6B
BioCryst Pharmaceuticals (BCRX)
$1.5B
Guardian Pharmacy Services (GRDN)
$1.5B
ARS Pharmaceuticals (SPRY)
$1.5B